The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections

International Orthopaedics

Volumn 37, Issue 7, 2013, Pages 1375-1380

  Jugun, Kheeldass ^a   Vaudaux, Pierre ^a   Garbino, Jorge ^a   Pagani, Leonardo ^a   Hoffmeyer, Pierre ^a   Lew, Daniel ^a   Uçkay, Ilker ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RIFAMPICIN;

ABSCESS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BACTEREMIA; BACTERIUM CULTURE; BONE INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GRAM POSITIVE OSTEOARTICULAR INFECTION; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; JOINT PROSTHESIS; KIDNEY GRAFT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; OSTEOSYNTHESIS MATERIAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROSPECTIVE STUDIES; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; TREATMENT OUTCOME;

EID: 84879418076     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-013-1856-y     Document Type: Article

References (17)

1. Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351:1645-1654
2. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ (2007) Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 30:202-209
3. Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, Pigrau Serrallach C, Guerra Farfán E, Amat Mateu C, Flores Sanchez X (2012) Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 67:1749-1754
4. Parra-Ruiz J, Dueñas-Gutiérrez C, Tomás- Jiménez C, Linares-Palomino JP, Garrido-Gomez J, Hernández-Quero J (2012) Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis 31:1771-1774
5. Gallagher JC, Huntington JA, Culshaw D, McConnell SA, Yoon M, Berbari E (2012) Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis 12:133
6. Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, Evans R (2012) Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 56:5626-5632
7. Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H, Yazdanpanah Y, Senneville E (2009) Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 15:1163-1169
8. Shinjoh M, Iketani O, Watanabe K, Shimojima N, Kudo M, Yamagishi H, Shimada H, Sugita K, Takahashi T, Mori T, Hasegawa N, Iwata S (2012) Safety and efficacy of linezolid in 16 infants and children in Japan. J Infect Chemother 18:591-596
9. Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson FB Jr (1999) Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig Drugs 8:1223-1238
10. Kern WV (2006) Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract 60:370-378
11. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47:1318-1323
12. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673-1681
13. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665
14. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948-2953
15. John A-K, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A (2009) Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 53:2719-2724
16. Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J (2003) Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52:89-95
17. Schaad HJ, Bento M, Lew DP, Vaudaux P (2006) Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis 6:74